Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;19(9):2075-83.
doi: 10.1111/jcmm.12618. Epub 2015 Jun 19.

Functions of Shp2 in Cancer

Free PMC article

Functions of Shp2 in Cancer

Jie Zhang et al. J Cell Mol Med. .
Free PMC article


Diagnostics and therapies have shown evident advances. Tumour surgery, chemotherapy and radiotherapy are the main techniques in treat cancers. Targeted therapy and drug resistance are the main focus in cancer research, but many molecular intracellular mechanisms remain unknown. Src homology region 2-containing protein tyrosine phosphatase 2 (Shp2) is associated with breast cancer, leukaemia, lung cancer, liver cancer, gastric cancer, laryngeal cancer, oral cancer and other cancer types. Signalling pathways involving Shp2 have also been discovered. Shp2 is related to many diseases. Mutations in the ptpn11 gene cause Noonan syndrome, LEOPARD syndrome and childhood leukaemia. Shp2 is also involved in several cancer-related processes, including cancer cell invasion and metastasis, apoptosis, DNA damage, cell proliferation, cell cycle and drug resistance. Based on the structure and function of Shp2, scientists have investigated specific mechanisms involved in cancer. Shp2 may be a potential therapeutic target because this phosphatase is implicated in many aspects. Furthermore, Shp2 inhibitors have been used in experiments to develop treatment strategies. However, conflicting results related to Shp2 functions have been presented in the literature, and such results should be resolved in future studies.

Keywords: DNA damage; Shp2; apoptosis; cancer; cell proliferation; drug resistance; invasion and metastasis.


Figure 1
Figure 1
Schematic diagram of the signalling and functions of Shp2 (1). In the presence of extracellular stimulation, including some cytokines and growth factors [e.g. interleukin (IL)6, epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), IFN), they binds to relevant receptor to activate the down-stream, as a result, Shp2 can be phosphorylated by the receptor tyrosine kinase (RTK), p-Shp2 binds to the Grb2/SOS to activate the Ras/Erk signalling, so that to enhance tumour invasion and metastasis. PTP activation and pTyr of Shp2 are the focus of research work, with a lot of conflicted results, it is not sure how Shp2 functions in different microenvironments, although signalling molecular inhibitors can treat and work partly, but it is necessary to ensure the safety and control the compensatory. (2) Gab1 can bind to Shp2 and activate the PI3K/Akt signalling to regulate tumour cell proliferation, tumour apoptosis and drug resistance. And still, the phosphatase activity of Shp2 plays a critical role in controlling these processes. (3) Shp2 participates in p53 signalling to regulate DNA damage and replication in cancer. (4) Stat3 can be phosphorylated to form dimer, Shp2 can dephosphorylate Stat3, but p-Stat3 is important for tumour progress, so the relationship and mechanism between p-Stat3 and Shp2 should be further investigated, and gives a more reasonable explaining for future research.

Similar articles

See all similar articles

Cited by 29 articles

See all "Cited by" articles


    1. Feng GS, Shen R, Heng HH, et al. Receptor-binding, tyrosine phosphorylation and chromosome localization of the mouse SH2-containing phosphotyrosine phosphatase Syp. Oncogene. 1994;9:1545–50. - PubMed
    1. Feng GS, Hui CC, Pawson T. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science. 1993;259:1607–11. - PubMed
    1. Feng GS, Pawson T. Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction. Trends Genet. 1994;10:54–8. - PubMed
    1. Hof P, Pluskey S, Dhe-Paganon S, et al. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92:441–50. - PubMed
    1. Bennett AM, Tang TL, Sugimoto S, et al. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci USA. 1994;91:7335–9. - PMC - PubMed

Publication types